Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841757 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 | |
| SCHEMBL17922948 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 | |
| SCHEMBL601116 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 | |
| SCHEMBL601118 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 | |
| SCHEMBL600728 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 | |
| SCHEMBL7872036 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 | |
| SCHEMBL16453643 | 0.87 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL7878962 | 0.86 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL7872025 | 0.86 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL600399 | 0.86 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104443-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-22 | — | — | WO | disclosed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| EP-3045448-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-3030234-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9296745-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2015018027-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015020933-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-02-12 | — | — | WO | disclosed |
| US-20140228377-A1 | METHYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2730573-A1 | METHYLPIPERIDINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010124055-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4, HRH4 | HSD17B10 1292/4885SMN1; SMN2 1489/4885BTK 494/4885 |
| US-20140228377-A1 | METHYLPIPERIDINE DERIVATIVE | HCRTR1, HCRTR2, MC4R | HSD17B10 1452/4885SMN1; SMN2 1457/4885BTK 2264/4885 |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | HSD17B10 627/4885SMN1; SMN2 3813/4885BTK 3579/4885 |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | GRM5, GRIK5, GRM2 | HSD17B10 2572/4885SMN1; SMN2 1209/4885BTK 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.